Non-Small Cell Lung Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Imfinzi Approved to Treat Stage III Non-Small Cell Lung Cancer - Monthly Prescribing Reference



Pharmacy Times
 
Imfinzi Approved to Treat Stage III Non-Small Cell Lung Cancer 
Monthly Prescribing Reference
AstraZeneca and MedImmune announced that the Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following ...
Durvalumab Approved by FDA for Reducing NSCLC Progression Pharmacy Times
Imfinzi Is First Immunotherapy Approved for Advanced Non-small Cell Lung Cancer in US Immuno-Oncology News
FDA expands approval of Imfinzi to reduce the risk of NSCLC progression European Pharmaceutical Review
Pharmacy Today, American Pharmacists Association, pharmacist.com  -Cancer Therapy Advisor  -OncLive 
all 20 news articles » 


FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing - FDA.gov



OncLive
 
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing 
FDA.gov
?This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation,? said Richard Pazdur, M.D., director of the FDA's Oncology ...
FDA Approves Imfinzi for Locally Advanced Non-Small Cell Lung Cancer Curetoday.com
FDA Approves Durvalumab for Locally Advanced NSCLC OncLive
US FDA APPROVES IMFINZIŽ (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER PR Newswire (press release)
Medscape  -Reuters  -Healio 
all 13 news articles » 


Surgery Remains Imperative in Biomarker-Driven NSCLC Era - OncLive



OncLive
 
Surgery Remains Imperative in Biomarker-Driven NSCLC Era 
OncLive
What other types of patients with NSCLC would benefit from having surgical resection? Specifically, in the metastatic setting, these will be people who have oligometastatic disease or very few sites of metastatic foci, had a good response, and clearly ...

 


Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer - AJMC.com Managed Markets Network



Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer 
AJMC.com Managed Markets Network
Commentary: The landscape for molecular testing in NSCLC is evolving rapidly. Although targeted therapy in patients with specific oncogenic genomic alterations is associated with superior outcomes, the use of molecular testing in clinical practice is ...

 


Avelumab Does Not Improve OS Over Docetaxel in NSCLC, Phase III Trial Shows - Targeted Oncology



Targeted Oncology
 
Avelumab Does Not Improve OS Over Docetaxel in NSCLC, Phase III Trial Shows 
Targeted Oncology
Early research had shown promise for avelumab in lung cancer. Results from the JAVELIN Solid Tumor trial presented in December 2016 at the IASLC 17th World Conference on Lung Cancer showed that after a median follow-up of 13 weeks, the objective ...

 


Ramalingam Highlights Immunotherapy Advances in NSCLC - OncLive



OncLive
 
Ramalingam Highlights Immunotherapy Advances in NSCLC 
OncLive
In the phase III KEYNOTE-189 study, the combination of pembrolizumab (Keytruda) with chemotherapy in the frontline setting improved survival in patients with nonsquamous NSCLC. In this trial, which is the confirmatory trial for the FDA approval of ...

 


Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC - OncLive



OncLive
 
Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC 
OncLive
In a trial combining immunotherapy with chemotherapy, the phase III KEYNOTE-189 study?the confirmatory trial for the May 2017 FDA approval of pembrolizumab (Keytruda) with carboplatin/pemetrexed?demonstrated improved survival in the frontline ...

 


Abscopal Effect Induction Among Patients With Metastatic Non-Small Cell Lung Cancer - Targeted Oncology



Targeted Oncology
 
Abscopal Effect Induction Among Patients With Metastatic Non-Small Cell Lung Cancer 
Targeted Oncology
The prognosis for patients with metastatic non?small cell lung cancer (NSCLC) is poor. However, with recent trials showing improved overall survival with checkpoint inhibitors compared with standard chemotherapy, disease management is changing ...

 


ALK Inhibitors Continue to Reshape Treatment in NSCLC - OncLive



OncLive
 
ALK Inhibitors Continue to Reshape Treatment in NSCLC 
OncLive
Salgia: I discussed many ALK trials in NSCLC. I was one of the physicians involved in bringing crizotinib to fruition. When we designed the clinical trial initially, that was the compound known as PF02341066. Based on that, it was supposed to be a MET ...

and more » 


Avelumab Falls Short in Phase III NSCLC Trial - OncLive



OncLive
 
Avelumab Falls Short in Phase III NSCLC Trial 
OncLive
Early research had shown promise for avelumab in lung cancer. Results from the JAVELIN Solid Tumor trial presented in December 2016 at the IASLC 17th World Conference on Lung Cancer showed that after a median follow-up of 13 weeks, the objective ...
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab ... PR Newswire (press release)
Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated ... Canada NewsWire (press release)
Merck KGaA and Pfizer's Avelumab fails in trial MarketWatch
BioWorld Online 
all 27 news articles »